SCHEMBL6026448

SCHEMBL6026448

O=S(=O)(Nc1ncco1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 3/20 0.56
▸ SCN9A Q15858 3/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ IL1RN P18510 1/20 0.48
▸ KEAP1 Q14145 1/20 0.48
▸ ERAP1 Q9NZ08 1/20 0.48
▸ CYP2C9 P11712 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SLC40A1 Q9NP59 2/20 0.45
▸ G6PD P11413 1/20 0.45
▸ NFKBIA P25963 1/20 0.45
▸ AGTR1 P30556 1/20 0.45
▸ METAP2 P50579 1/20 0.45
▸ METAP1 P53582 1/20 0.45
▸ GLO1 Q04760 1/20 0.45
▸ PAX8 Q06710 1/20 0.45
▸ ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28919283 0.83 LMNA (0.57) NPSR1CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL8126003 0.81 SCN9A (0.44) HSD11B1SCN9A
SCHEMBL31086043 0.79 SCN9A (0.48) HSD11B1SCN9AIDH2
SCHEMBL7404641 0.79 SCN9A (0.53) HSD11B1SCN9A
SCHEMBL10420864 0.78 EDNRA (0.48) ALDH1A1KMT2AATMTDP1
SCHEMBL8110606 0.76 HSD11B1 (0.48) HSD11B1SCN9ACYP2C9POLB
SCHEMBL8125378 0.75 LMNA (0.44) SCN9ACYP2C9ALDH1A1MEN1PKM
SCHEMBL31596399 0.73 SCN9A (0.59) SCN9A
SCHEMBL17576883 0.72 GLO1 (0.39) SCN9AKEAP1ALDH1A1GLO1
SCHEMBL332569 0.72 TSHR (0.70) NPSR1IL1RNKEAP1ERAP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521270-A Malonate compound containing N-oxazole benzene sulfonamide group, preparation method and application 贵州理工学院 2022-12-27 — — CN disclosed
US-9486422-B2 Small molecule inhibitors of Mcl-1 and the uses of thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-11-08 — — US disclosed
US-20140235702-A1 SMALL MOLECULE INHIBITORS OF MCL-1 AND THE USES OF THEREOF WAYNE STATE UNIVERSITY 2014-08-21 — — US disclosed
CN-103965180-A Benzenesulfonamideoxazole and thiazole kinase inhibitor TONGHUA JIDA PHARMACEUTICAL CO LTD 2014-08-06 — — CN disclosed
CN-103965180-A Benzenesulfonamideoxazole and thiazole kinase inhibitor TONGHUA JIDA PHARMACEUTICAL CO LTD 2014-08-06 — — CN disclosed
WO-2013052943-A2 SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHGIAN (US) 2013-04-11 — — WO disclosed
US-6998415-B2 Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma PHARMACIA CORPORATION (US) 2006-02-14 — — US disclosed
US-6875785-B2 Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors PHARMACIA CORPORATION (US) 2005-04-05 — — US disclosed
US-20040248943-A9 Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors PHARMACIA CORPORATION 2004-12-09 — — US disclosed
US-20040147565-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors G.D. SEARLE & CO. 2004-07-29 — — US disclosed
US-20010056189-A1 Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors TALLEY JOHN J (US) 2001-12-27 — — US disclosed
US-6090834-A ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS G.D. SEARLE & CO. (US) 2000-07-18 — — US disclosed
EP-0995747-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors G.D. SEARLE & CO. (US) 2000-04-26 — — EP disclosed
EP-0828736-A1 SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS G.D. SEARLE & CO. (US) 1998-03-18 — — EP disclosed
EP-0825989-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1998-03-04 — — EP disclosed
WO-1996038442-A1 SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS G.D. SEARLE & CO. (US) 1996-12-05 — — WO disclosed
WO-1996036617-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-11-21 — — WO disclosed
US-4602940-A HERBICIDES, PLANT GROWTH REGULATOR E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-07-29 — — US disclosed
US-4465505-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-08-14 — — US disclosed
US-4332796-A MICROCRYSTALS COATED WITH MIXTURES OF PHOSPHOLIPIDS AND NONIONIC SURFACTANTS LABORATORIOS BAGO S.A. (AR) 1982-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147565-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors ALOX5, ALOX12, ALOX15 HSD11B1 495/4885SCN9A 4329/4885NPSR1 2222/4885
US-20040248943-A9 Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors ALOX5, ALOX15, ALOX12 HSD11B1 244/4885SCN9A 4701/4885NPSR1 3570/4885
US-20140235702-A1 SMALL MOLECULE INHIBITORS OF MCL-1 AND THE USES OF THEREOF MCL1, BCL2L1, BCL2L11 HSD11B1 2393/4885SCN9A 3812/4885NPSR1 4194/4885
US-20010056189-A1 Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors ALOX5, ALOX15, ALOX12 HSD11B1 241/4885SCN9A 4746/4885NPSR1 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback